Eikon Therapeutics, Inc.
EIKN
$10.73
$0.020.19%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 17.93M | 17.29M | 17.73M | 19.14M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 93.39M | 87.34M | 82.96M | 85.33M | |
| Operating Income | -93.39M | -87.34M | -82.96M | -85.33M | |
| Income Before Tax | -88.41M | -82.96M | -79.66M | -105.21M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -88.41M | -82.96M | -79.66M | -105.21M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -88.41M | -82.96M | -79.66M | -105.21M | |
| EBIT | -93.39M | -87.34M | -82.96M | -85.33M | |
| EBITDA | -88.27M | -82.12M | -77.57M | -81.12M | |
| EPS Basic | -1.63 | -2.46 | -26.38 | -36.94 | |
| Normalized Basic EPS | -1.02 | -1.54 | -16.44 | -17.75 | |
| EPS Diluted | -1.63 | -2.46 | -26.38 | -36.94 | |
| Normalized Diluted EPS | -1.02 | -1.54 | -16.44 | -17.75 | |
| Average Basic Shares Outstanding | 54.14M | 33.70M | 3.02M | 2.85M | |
| Average Diluted Shares Outstanding | 54.14M | 33.70M | 3.02M | 2.85M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |